Pharmanutra S.p.A (PHN) Fair Value & Analysis
Healthcare · IT · Market cap €874M
Fair value as of: Jul 18, 2026
From 24 valuation models · updated 23 days ago
Share price −6.1% over the past month.
A strong business, but screening 46% overvalued on our models.
What matters now
- A high-quality business (quality 76/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (€67.54). The favourable scenario is already priced in.
- A fairly wide model range (€27.90 to €67.54) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range €33.35 – €92.90 · fair‑value band €27.90 – €67.54 · the €84.60 price screens above the €45.96 fair value. Dashed = 300-day average. As of Jul 18, 2026.
Analysis
Pharmanutra S.p.A (PHN) currently trades at €84.60, while our model-based Fair Value estimate is €45.96, implying the stock looks roughly 45.7% overvalued today. The Quality Score stands at 76/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Pharmanutra S.p.A generated revenue of €139M at a net margin of 15.1%. Revenue grew 25.6% year over year. It earns a return on equity of 30.2%. The stock trades on a trailing P/E of 41.5. Fundamentals as of Jul 18, 2026
Our scenario range runs from €27.90 (bear case) to €67.54 (bull case); at €84.60, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 12% below its 52-week high and 122% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -46%, PHN screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (€51.95) versus Asset-Based (€4.99). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 82
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally.
Full company description
Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for muscle and joint recovery in physiotherapy and sports. The company also sells instrumentation and software for body bioimpedance analysis through agents, distributors, and online sales. Pharmanutra S.p.A. was founded in 2000 and is headquartered in Pisa, Italy.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pharmanutra S.p.A reported revenue of €133M in FY2025 versus €68.6M in FY2021, a compound +18.0%/yr. Reported net income was €20.0M in FY2025, compounding +9.8%/yr from FY2021.
PHN screens 46% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Pharmanutra S.p.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pharmanutra S.p.A (PHN) overvalued or undervalued?
What is the fair value of PHN?
What is the quality score of PHN?
What is the revenue of Pharmanutra S.p.A (PHN)?
What is the net profit margin of PHN?
Does Pharmanutra S.p.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Pharmanutra S.p.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.